UK markets closed

Cosmo Pharmaceuticals N.V. (0RGI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
70.96+0.65 (+0.93%)
At close: 05:50PM BST
Currency in CHF

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.19
52-week change 319.44%
S&P500 52-week change 320.07%
52-week high 371.40
52-week low 333.75
50-day moving average 363.20
200-day moving average 348.12

Share statistics

Avg vol (3-month) 31.44k
Avg vol (10-day) 31.06k
Shares outstanding 515M
Implied shares outstanding 6N/A
Float 88.49M
% held by insiders 147.15%
% held by institutions 110.01%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 32.00
Trailing annual dividend yield 32.84%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 1.19%
Operating margin (ttm)9.62%

Management effectiveness

Return on assets (ttm)1.16%
Return on equity (ttm)0.30%

Income statement

Revenue (ttm)96.72M
Revenue per share (ttm)6.01
Quarterly revenue growth (yoy)-12.40%
Gross profit (ttm)N/A
EBITDA 25.78M
Net income avi to common (ttm)1.15M
Diluted EPS (ttm)1.30
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)50.27M
Total cash per share (mrq)3.13
Total debt (mrq)1.84M
Total debt/equity (mrq)0.42%
Current ratio (mrq)4.41
Book value per share (mrq)26.58

Cash flow statement

Operating cash flow (ttm)33.62M
Levered free cash flow (ttm)15.96M